Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Age-related macular degeneration ... Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST, President Oh Sang-Rok) has developed a new therapeutic agent ...

The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window ... Unlock insights into the Age-related Macular Degeneration Market: discover drug uptake patterns ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...